Clinical

Vancouver tests prescription heroin

The north-of-the-border solution comes amid climbing heroin abuse in the US.

Five things for pharma marketers to know: Monday, November 24

Five things for pharma marketers to know: Monday, November 24

By

BioMarin to acquire Dutch biotech Prosensa; Woodcock says significant efficacy key to Breakthrough Therapy designation; Stryker considers $16 billion bid for UK devicemaker Smith and Nephew.

Five things for pharma marketers to know: Friday, November 21

Five things for pharma marketers to know: Friday, November 21

By By By

EMA revises its conflict of interest policy; AbbVie all-oral HCV combo drug receives positive EU recommendation; Merck may help NewLink Genetics scale production of its Ebola vaccine.

Analyses support Pradaxa safety profile

Analyses support Pradaxa safety profile

By

Results of two post-market studies, conducted in part by Boehringer Ingelheim, corroborate the billion-dollar blood thinner's benefit/risk profile.

PCSK9s stalk Merck's Vytorin

PCSK9s stalk Merck's Vytorin

By

A head-to-head comparison between Sanofi and Regeneron's experimental PCSK9 shows alirocumab lowers LDL levels more effectively than Merck's Zetia, which is part of the just-acquitted Vytorin.

Study finds new benefits in highly promising heart drug

A pipeline drug from Novartis has the potential to alter the progression of heart disease and keep patients out of the hospital.

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

By

Patients taking Vytorin experienced a 6.4% reduced relative risk for cardiovascular events, the company said.

Inovio sticks with prostate cancer drug

The Pennsylvania company says it will continue to develop its IO treatment, even without Roche's support.

2015 an "important year" for Pfizer's IO pipeline, analysts say

A 4-1BB agonist highlights a discussion with analysts on the drug giant's immunoncology pipeline, with a number of combination options to be tested next year.

Merck's weekly DPP-IV on par with daily Januvia: study

Merck's weekly DPP-IV on par with daily Januvia: study

By

Merck unveiled the DPP-IV clinical trial results at the European Association for the Study of Diabetes Annual meeting Thursday.

BI Spiriva combo has Phase-III success

BI Spiriva combo has Phase-III success

By

The company said in a statement that the findings indicated the Spiriva-Striverdi combination treatment could help patients "return to a more independent life."

Lilly basal bests Lantus in T1D, despite safety concerns

Lilly basal bests Lantus in T1D, despite safety concerns

By

Lilly's long-acting insulin showed it's more effective in type 1 diabetics than Lantus, but concerns about its overall profile persist.

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low on doc awareness

By

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Novartis may have game-changing drug

Novartis may have game-changing drug

By

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

By

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

By

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

DOJ closes Brilinta investigation

By

AstraZeneca announced the end of the investigation Tuesday.

Kyprolis fails to wow in survival trial

Kyprolis fails to wow in survival trial

By

Amgen now hopes a separate study will be enough to support the drug's advancement to a second-line therapy, but the lackluster results may impinge on its EU filing schedule.

Kyprolis data fuel Amgen oncology aspirations

Kyprolis data fuel Amgen oncology aspirations

By

Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Study questions HDL medication benefit

A study indicates they may do little to reduce the risk of stroke or heart attack.

NIH: HPV test beats Pap for cancer assessment

HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

By

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.

Alzheimer's study to use healthy patients

Novartis and the nonprofit Banner Alzheimer's Institutes are testing a theory that treating healthy patients could prevent or delay Alzheimer's disease.

Lilly's Cyramza misses liver-cancer target

Cyramza patients had more favorable overall survival rates than placebo patients, but the differences were not statistically significant.

Study unlinks testosterone and heart attacks

The Wall Street Journal notes that a new study on testosterone therapy has some weaknesses, including its sole focus on men who received injections—leaving out pills, patches and gels.

Study links DPP-IV medication to heart failure, hospitalization

Editorial says risk is small, researchers say it could be clinically relevant.

ACP says no need for pelvic exams

The American College of Physicians says most women do not need an annual pelvic exam. The American College of Obstetrics and Gynecologists disagrees.

FDA wants male breast cancer patients

The regulator wants men to be part of breast cancer clinical trials.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters